The company’s trial of Haduvio met its primary and secondary endpoints in reducing coughing fits across patients by 53%.

Protagonist Therapeutics (PTGX) announced topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...

CervoMed has announced positive results from the extension phase 2b RewinD-LB study of neflamapimod for dementia with Lewy ...

GlobalData predicts that icotrokinra will reach blockbuster status in 2029, with the drug forecast to generate sales of ...

Pliant Therapeutics shares dropped 52% to $1.64, after the company said it was discontinuing a phase 2b trial for bexotegrast in patients with idiopathic pulmonary fibrosis. The stock hit its 52-week ...

The eight-week, quadruple-masked, dose-finding, core stage of the Phase 2b clinical trial is evaluating the efficacy and safety of a single ...

Beckley Psytech has completed subject enrolment for the core stage of the global Phase IIb clinical trial of patent-protected ...

Explore SGMT's breakthrough MASH therapy, Denifanstat, with FDA designation & Phase 3 progress. Click here to read my most ...

The AHFIRM trial did not demonstrate a beneficial effect of larsucosterol on 90-day mortality or the need for liver transplant among patients with severe alcohol-associated hepatitis, or AH, according ...

Alto Neuroscience, Inc.’s ANRO share price has dipped by 10.13%, which has investors questioning if this is right time to buy ...

Trevi Therapeutics, Inc.’s TRVI share price has surged by 41.16%, which has investors questioning if this is right time to sell.